

Supplemental Material for:

Quality of life and symptom burden among myeloproliferative neoplasm patients: Do symptoms impact quality of life?

Blake T. Lenglais, et al.


- Supplemental Table 1. Study group characteristics by MPN disease subgroup
- Supplemental Figure 1. Individual symptom severity, prevalence, and correlation with quality of life for each MPN disease subgroup.
- Supplemental Figure 2. Summary measure impact on quality of life: Mean of the (x) most severe symptom scores for the group
- Supplemental Figure 3. Summary measure impact on quality of life: Mean of the (x) most severe symptom scores for each patient
- Supplemental Figure 4. Summary measure impact on quality of life: Total number of symptoms at/above each symptom severity threshold
- Supplemental Figure 5. Summary measure impact on quality of life: At least one symptom at/above each symptom severity threshold

Supplemental Table 1. Study Group Characteristics by MPN Disease Subgroup

	ET (N=625)	PV (N=456)	MF (N=335)	Overall (N=1416)	<i>P</i>
Age, mean (SD)	57.2 (15.1)	60.4 (13.0)	58.5 (11.7)	58.5 (13.8)	<0.001 ¹
Sex, n (%)					<0.001 ²
Female	383 (62.5%)	191 (42.4%)	165 (49.3%)	739 (52.9%)	
Male	230 (37.5%)	259 (57.6%)	170 (50.7%)	659 (47.1%)	
QLQ-C30 GHS/QoL, mean (SD)	70.0 (21.6)	66.7 (22.4)	59.2 (24.1)	66.4 (22.9)	<0.001 ^{3*}
MPN-SAF TSS, mean (SD)	1.7 (1.5)	1.9 (1.6)	2.6 (1.7)	2.0 (1.6)	<0.001 ^{1*}
Duration of MPN diagnosis, median years (range)	5 (0.0-27.0)	6 (0.0-36.0)	5.5 (0.0-43.0)	5 (0.0-43.0)	0.12 ³


¹ANOVA ²Chi-Square ³Kruskal Wallis * Linear regression model adjusting for age and sex

Supplemental Figure 1. Individual Symptom Severity, Prevalence, and Correlation with Quality of Life by MPN Subgroup




Symptom severity was measured as 0 (absent) to 10 (worst imaginable) using the MPN Symptom Assessment Form. Prevalence was defined as a symptom score greater than or equal to 1. Pearson correlations shown are between each symptom and quality of life as measured by the Global Health Status/Quality of Life scale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30.


Supplemental Figure 2. Summary measure impact on quality of life: Mean of the (x) most severe symptom scores for the group



Supplemental Figure 3. Summary measure impact on quality of life: Mean of the (x) most severe symptom scores for each patient



Supplemental Figure 4. Summary measure impact on quality of life: Total number of symptoms at/above each symptom severity threshold



Supplemental Figure 5. Summary measure impact on quality of life: At least one symptom at/above each symptom severity threshold

